- Home
- RAYA vs RNAZ Comparison
RAYA vs RNAZ Comparison
Compare RAYA & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAYA
- RNAZ
- Stock Information
- Founded
- RAYA 2019
- RNAZ 2016
- Country
- RAYA China
- RNAZ United States
- Employees
- RAYA N/A
- RNAZ N/A
- Industry
- RAYA Metal Fabrications
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- RAYA Consumer Discretionary
- RNAZ Health Care
- Exchange
- RAYA Nasdaq
- RNAZ Nasdaq
- Market Cap
- RAYA 6.1M
- RNAZ 6.1M
- IPO Year
- RAYA 2022
- RNAZ 2021
- Fundamental
- Price
- RAYA $0.05
- RNAZ $10.26
- Analyst Decision
- RAYA
- RNAZ Strong Buy
- Analyst Count
- RAYA 0
- RNAZ 1
- Target Price
- RAYA N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- RAYA 97.6M
- RNAZ 32.0K
- Earning Date
- RAYA 01-01-0001
- RNAZ 08-14-2025
- Dividend Yield
- RAYA N/A
- RNAZ N/A
- EPS Growth
- RAYA N/A
- RNAZ N/A
- EPS
- RAYA N/A
- RNAZ N/A
- Revenue
- RAYA $30,300,360.00
- RNAZ N/A
- Revenue This Year
- RAYA $20.95
- RNAZ N/A
- Revenue Next Year
- RAYA N/A
- RNAZ N/A
- P/E Ratio
- RAYA N/A
- RNAZ N/A
- Revenue Growth
- RAYA 49.10
- RNAZ N/A
- 52 Week Low
- RAYA $0.05
- RNAZ $6.15
- 52 Week High
- RAYA $3.35
- RNAZ $739.20
- Technical
- Relative Strength Index (RSI)
- RAYA 26.51
- RNAZ 48.60
- Support Level
- RAYA $0.05
- RNAZ $9.42
- Resistance Level
- RAYA $0.06
- RNAZ $11.70
- Average True Range (ATR)
- RAYA 0.01
- RNAZ 0.80
- MACD
- RAYA 0.07
- RNAZ -0.24
- Stochastic Oscillator
- RAYA 4.44
- RNAZ 31.60
About RAYA Erayak Power Solution Group Inc.
Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from four products namely inverters, chargers, power bank, and gasoline generators. The company generates the majority of its revenue from Inverters. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.